Search

Recent research from Charite University Hospital and School of Medicine in Berlin, Germany, focuses on identifying truly HPV-driven head and neck squamous cell carcinoma (HNSCC) using a QuantiGene-Molecular-Profiling-Histology (QG-MPH) assay. The study found that patients with transcriptionally active HPV had better outcomes compared to those with discordant diagnostic patterns. Incorporating molecular mRNA profiling by QG-MPH alongside p16 IHC may lead to more precise prognosis prediction and therapeutic decision-making for HNSCC patients. This study provides valuable insights into improving patient outcomes and treatment strategies for head and neck cancer. [Extracted from the article]

A study conducted in Tongliao, People's Republic of China, focused on developing a delivery system for triptolide (TPL) using folate-modified mixed pluronic micelles. The micelles showed promising results in reducing HepG2 cell viability and targeting tumor tissue in a mouse model of hepatocellular carcinoma. The research concluded that the system, FA-F-127/F-68-TPL, represents a potential antitumor drug delivery system with active/passive targeting capabilities and notable cytotoxicity against liver cancer cells. The study was published in Polymers and can be accessed online for further information. [Extracted from the article]

A recent study from Tel Aviv University discusses the challenges of managing children with syndromes linked to an increased risk of benign and malignant neoplasms, focusing on cancer surveillance. The research emphasizes the importance of early detection and intervention to reduce morbidity associated with such neoplasms. Various rare conditions, such as Ollier disease, Maffucci syndrome, and Hereditary leiomyomatosis and renal cell carcinoma syndrome, are reviewed, highlighting the need for surveillance and prompt intervention when necessary. The study provides clinical recommendations tailored to each syndrome's age-specific tumor risk profile, emphasizing the importance of educating patients and families about potential malignancy risks. [Extracted from the article]

Researchers at the Koppal Institute of Medical Sciences in Karnataka, India, have published a case report on squamous cell carcinoma in a patient with ichthyosis hystrix Curth-Macklin, a rare congenital skin condition. The report highlights the importance of early diagnosis, treatment, and regular follow-up for patients with this condition, as they may be at risk for developing malignancies over time. This research underscores the need for increased awareness and monitoring of individuals with ichthyosis hystrix to ensure timely intervention. [Extracted from the article]

A recent study conducted by the University of Toronto compared the effectiveness of stereotactic body radiotherapy (SBRT) versus sorafenib alone in patients with locally advanced hepatocellular carcinoma (HCC). The research found that SBRT was associated with a clinically important, but not statistically significant, improvement in overall survival compared to sorafenib alone. The study, which was supported by the NIH National Cancer Institute, analyzed data from 177 eligible patients and concluded that SBRT may offer benefits in the treatment of HCC. For more information, the full report can be found in JAMA Oncology. [Extracted from the article]

A recent study from Army Medical University in Chongqing, China, focused on a rare case of Rosai-Dorfman disease (RDD) with pleural involvement in a 61-year-old patient. The patient, who also had a history of clear cell renal cell carcinoma, underwent surgical excision for the pleural lesion. The study highlights the importance of considering RDD as a differential diagnosis for nodular pleural masses or soft tissue lesions, emphasizing the need for pathology and immunohistochemistry analysis for definitive diagnosis. [Extracted from the article]

A patent application titled "Cancer Detection And Classification Using Methylome Analysis" was published online by inventors from Toronto, CA. The application focuses on detecting circulating tumor DNA (ctDNA) from cancer cells in a non-invasive manner using methylome analysis. The method involves sequencing cell-free DNA, comparing sequences to control samples, and identifying cancer cell DNA based on similarities. This innovative approach aims to improve cancer detection sensitivity, especially in cases with low levels of ctDNA. [Extracted from the article]

Researchers have submitted a patent application for the use of FGFR tyrosine kinase inhibitors in treating advanced solid tumors. The application focuses on administering erdafitinib to patients with specific FGFR fusions or genetic alterations across various types of cancer, including cholangiocarcinoma, pancreatic cancer, high-grade glioma, and ovarian cancer. The patent application highlights the potential of FGFR inhibitors in personalized cancer therapy based on genetic abnormalities. [Extracted from the article]

A recent study conducted at Moti Lal Nehru Medical College explored the correlation between Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), and Monocyte Lymphocyte Ratio (MLR) in different stages of breast cancer. The study included 59 female patients with confirmed breast cancer diagnoses and found no significant correlations between NLR, PLR, or MLR and the clinical stages of breast carcinoma. However, there was a statistically significant difference in monocyte counts across histological grades, suggesting a potential role for monocytes in disease progression. Further research is needed to investigate the role of these inflammatory markers in tumor biology. [Extracted from the article]

Researchers from Sri Ramachandra Institute of Higher Education and Research published a case report on a 62-year-old woman with simultaneous Breast Carcinoma and Endometrial Carcinoma, a rare occurrence. The patient presented with postmenopausal bleeding and was found to have a breast mass and thickened endometrium. She underwent various diagnostic tests and surgeries, revealing mucinous carcinoma in the breast and tumour cells in the endometrium. The study highlights the unique presentation of these twin malignancies and emphasizes the importance of early detection and treatment. [Extracted from the article]

A recent study from Chengdu University examined the relationship between dietary fiber intake and cancer outcomes, focusing on colon cancer prevention. The study analyzed existing systematic reviews and meta-analyses, finding that high fiber intake significantly lowers the risk of various cancers, including colon cancer. The research suggests that increased dietary fiber intake is linked to reduced cancer risk and improved outcomes, emphasizing the importance of dietary fiber in cancer prevention and care. [Extracted from the article]

A study conducted at Hashemite University in Zarqa, Jordan, explored the presence of triple viral infections in advanced breast cancer cases. The research highlighted three instances of advanced breast cancer associated with HPV, CMV, and BLV infections, suggesting a possible correlation between viral co-infections and breast cancer aggressiveness. The findings indicate a need for further investigation into the role of viral infections in cancer development and prognosis, potentially leading to targeted preventive measures such as vaccinations. [Extracted from the article]

A recent study from Capital Medical University in Beijing, China, focused on the accuracy of arterial-phase dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting cervical stromal invasion in patients with endometrial carcinoma. The study found that arterial-phase DCE-MRI is a feasible and effective method for detecting cervical stromal invasion, offering a time-saving alternative to the delayed-phase approach. Factors such as the distribution of Nabothian cysts and lesion location were identified as influencing the assessment of cervical stromal invasion. [Extracted from the article]

University of Miami researchers have published a study on Rosai-Dorfman disease (RDD) presenting with FDG-avid breast masses and axillary lymph nodes in a patient with a recent diagnosis of endometrial carcinoma. The case study highlights the unique characteristics of RDD, which can mimic malignant lymphoproliferative disease and present a diagnostic dilemma. The research emphasizes the importance of thorough evaluation and diagnostic procedures in cases where clinical and radiological presentations are suspicious for breast cancer. [Extracted from the article]

A recent report from Saitama Medical University in Japan discusses a case of a 64-year-old man with cirrhosis who developed fulminant type 1 diabetes shortly after receiving treatment for hepatocellular carcinoma with durvalumab and tremelimumab. The patient had no prior history of diabetes mellitus. This rare immune-mediated adverse event emphasizes the need for prompt attention due to its severe and emergent nature. The research findings highlight the importance of monitoring patients for potential complications following the initiation of certain cancer treatments. [Extracted from the article]

The article discusses the role of Kinase Suppressor of Ras 1 (KSR1) in small-cell lung cancer (SCLC) tumor initiation and cisplatin resistance. It highlights KSR1 as a critical regulator of SCLC tumor-initiating cells (TICs) and its mediation of cisplatin resistance in SCLC. The study suggests that KSR1 disruption may enhance the effectiveness of cisplatin in targeting cells responsible for therapeutic resistance and tumor initiation, making KSR1 a potential therapeutic target for SCLC treatment. [Extracted from the article]

Researchers at the First Affiliated Hospital conducted a study on renal cell carcinoma (RCC) and found that the long non-coding RNA OSTM1-AS1 plays a crucial role in promoting RCC progression by interacting with miR-491-5p and upregulating MMP-9. The study revealed that OSTM1-AS1 is highly expressed in RCC tissue and cell lines, and its suppression led to inhibition of tumor growth in mice. This research suggests that targeting the OSTM1-AS1/miR-491-5p/MMP-9 axis could be a promising therapeutic approach for RCC treatment. [Extracted from the article]

A recent study from Shandong First Medical University highlights the potential of LncRNA HOXA10-AS as a novel biomarker and therapeutic target in various human cancers. The research emphasizes the clinical significance of HOXA10-AS in cancers such as esophageal carcinoma, gastric cancer, and pancreatic cancer, among others. The findings suggest that HOXA10-AS could be a valuable tool for cancer prognosis and treatment, making it a promising area for further research and development. [Extracted from the article]

A study published in Gene Therapy Weekly explores the potential of dronedarone, an FDA-approved drug used for atrial fibrillation, in inhibiting the proliferation of esophageal squamous cell carcinoma (ESCC) through the CDK4/CDK6-RB1 axis. The research reveals that dronedarone significantly suppresses ESCC cell growth by targeting key regulators of the cell cycle, providing a promising therapeutic candidate for ESCC treatment. In vitro and in vivo experiments demonstrate the drug's efficacy in reducing tumor size and proliferation markers, highlighting its potential for further investigation in ESCC chemoprevention and treatment. [Extracted from the article]

Researchers from Nanjing Normal University have discovered that the natural product Salidroside enhances the sensitivity of 5-fluorouracil in treating hepatocellular carcinoma (HCC) by inducing mitophagy via the YIPF5 pathway. This combination therapy showed promising results in a mouse model of HCC, suggesting a potential new approach to treating this challenging cancer. The study highlights the importance of drug repurposing and natural product screening in developing innovative cancer treatments. [Extracted from the article]

The article from Cancer Weekly discusses the role of Kinase Suppressor of Ras 2 (KSR2) in promoting self-renewal and clonogenicity of small-cell lung carcinoma (SCLC) cells, particularly in the ASCL1 subtype of SCLC tumors. KSR2 is a molecular scaffold that enhances Raf/MEK/ERK signaling and is expressed in pulmonary neuroendocrine cells, which are identified as cells of origin for SCLC-A tumors. Disruption of KSR2 inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo, suggesting KSR2 as a potential therapeutic target for ASCL1-subtype SCLC tumors. [Extracted from the article]

The article discusses a clinical trial, NCT06762470, focusing on the prognostic value of the circulating lymphocyte CD4/CD8 ratio in patients with non-metastatic nasopharyngeal carcinoma. The study aims to evaluate the significance of this ratio as a prognostic marker before treatment. The trial is being conducted at multiple centers and is actively recruiting participants in China, with a target enrollment of 325 patients. The primary outcome measures include progression-free survival, overall survival, distant metastasis-free survival, and locoregional recurrence-free survival over a three-year period. [Extracted from the article]

A patent application titled "Use Of Gcn2 Inhibitors In Treating Cancer" was published online, detailing a method of treating cancer by administering a GCN2 inhibitor to individuals with low expression or activity of a urea cycle enzyme. The inventors highlight the importance of arginine in cell processes and the potential of GCN2 inhibitors as cancer therapeutics. The application outlines methods for predicting responsiveness to GCN2 inhibitors and inhibiting tumor growth or cell proliferation in various types of cancer, emphasizing the need for targeted treatments based on urea cycle enzyme levels. [Extracted from the article]

A patent application titled "Methods, Compositions, And Systems To Detect Head And Neck Cancer In Saliva Samples" by inventor Gerald J. Wallweber aims to develop improved biomarkers for Head and Neck Squamous Cell Carcinoma (HNSCC). The application focuses on detecting HNSCC in individuals using saliva samples and measuring biomarkers associated with the disease, such as AIM2, CDSN, INHBA, MMP1, MMP9, and MMP10. The goal is to identify individuals at risk for HNSCC, monitor them, and potentially administer treatments. The application highlights the importance of early detection for improving patient survival rates and emphasizes the need for reliable biomarkers in diagnosing and preventing HNSCC. [Extracted from the article]

A recent study conducted by researchers at Nantong University in China focused on the role of POU3F4 in various cancers, exploring its expression patterns, prognostic implications, and functional roles in tumor immunity. The study utilized data from multiple sources to investigate the potential carcinogenic effects of POU3F4, revealing that its expression varies across different cancer types and is associated with prognosis, DNA and RNA methylation, immune cell infiltration, and drug resistance. In vitro experiments showed that POU3F4 enhances cell viability, proliferation, and migration in glioblastoma multiforme (GBM), suggesting its significance as a prognostic marker in diverse malignancies. [Extracted from the article]

A recent study conducted at Baskent University Faculty of Medicine explored the immunohistochemical profile of basosquamous carcinoma (BSC) and its clinicopathological associations. The research analyzed 104 BSC cases diagnosed between 1996 and 2017, revealing high proliferation and ulceration rates. The study highlighted correlations between various immunohistochemical markers and clinicopathological characteristics, shedding light on the potential prognostic significance of these markers for BSC. Long-term follow-up studies are recommended to further clarify these findings. [Extracted from the article]

Researchers at Ditmanson Medical Foundation Chia-Yi Christian Hospital in Taiwan conducted a study on urothelial cancer, focusing on the potential synergistic effects of combining doxorubicin with vorinostat in therapy. The study found that the combination treatment led to decreased cell viability and induced cell death in human bladder cancer cells. The researchers concluded that this combination therapy could be a promising new treatment for urothelial bladder cancer, potentially reducing the side effects of high-dose doxorubicin. [Extracted from the article]

Researchers from Binzhou Medical University in China conducted a study on the effectiveness and safety of combining hepatic arterial infusion chemotherapy (HAIC) with lenvatinib and tislelizumab for advanced hepatocellular carcinoma (HCC) with high tumor burden. The study included 162 treatment-naive patients with advanced HCC, and after propensity score matching, it was found that the group receiving HAIC showed significantly prolonged overall survival and progression-free survival compared to the group without HAIC. The researchers concluded that HAIC combined with lenvatinib and tislelizumab could be a promising treatment option for advanced HCC patients due to improved prognosis and acceptable safety. [Extracted from the article]

A recent study conducted at the Medical University of Plovdiv in Bulgaria focused on analyzing the expression of estrogen receptor alpha (ER alpha) and epidermal growth factor receptor (EGFR) in non-smoking women with lung adenocarcinoma. The research found that there is a correlation between the expression of EGFR mutation and the time of menopause, suggesting a relationship with hormonal and menstrual factors. The study concluded that the expression of ER alpha and EGFR in these women is likely influenced by sex hormones and menstrual factors. [Extracted from the article]

Researchers at Rockefeller University have reported new findings on liver cancer, specifically focusing on Fibrolamellar Hepatocellular Carcinoma (FLC). The study analyzed RNA-seq data from 1412 liver tumors to understand the pathogenesis of FLC and its relationship to other liver tumors. The research identified unique dysregulations in FLC tumors and studied metastases, finding small differences from primary tumors. This study provides valuable insights into the diverse disruptions of protein kinase A in liver cancer. [Extracted from the article]

A recent study conducted by researchers from Capital Medical University in Beijing, China, focused on the survival analysis of patients with hepatocellular carcinoma (HCC) based on the ratio of platelet count to spleen diameter. The study found that the platelet count/spleen diameter ratio (PSL) could predict the presence of esophagogastric varices and portal hypertension, which are risk factors for HCC recurrence. The researchers developed a novel nomogram using LASSO Cox regression, which showed higher predictive efficacy for 3-year overall survival in HCC patients. The study highlights the importance of PSL in predicting the prognosis of HCC patients and could potentially improve patient outcomes. [Extracted from the article]

A recent study conducted at the General Hospital of Ningxia Medical University in China aimed to develop a habitat imaging method for predicting early postoperative recurrence of hepatocellular carcinoma. The study involved a retrospective analysis of 344 patients who underwent liver resection for HCC, utilizing radiomics feature extraction and machine learning classification models. The research concluded that habitat analysis of sequential CT images can delineate distinct subregions within a tumor, providing valuable insights for early prediction of postoperative HCC recurrence. For more information, readers can refer to the article "Prediction of early postoperative recurrence of hepatocellular carcinoma by habitat analysis based on different sequence of contrast-enhanced CT" published in Frontiers in Oncology. [Extracted from the article]

A recent study conducted by researchers at Kurume University School of Medicine focused on the efficacy and safety of chemoradiotherapy (CRT) combined with local consolidative therapy (LCT) for patients with Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases. The study enrolled 19 patients and found that the treatment approach resulted in a 2-year survival rate of 68.4% and a response rate of 58%. The researchers concluded that this combined treatment strategy may extend survival and achieve local control for NSCLC with oligometastases. [Extracted from the article]

Researchers at the National Cancer Institute have developed a tissue factor (TF)-targeted near-infrared photoimmunotherapy (NIR-PIT) as a potential treatment for various types of cancer. The study found that TF expression was present in multiple cancer cell lines both in vitro and in vivo, and TF-targeted NIR-PIT led to cell death in a light dose-dependent manner. In animal models, TF-targeted NIR-PIT suppressed tumor growth and improved survival rates, showing promise as a treatment for different cancer types expressing TF. The research was published in Cancer Immunology, Immunotherapy and was supported by the National Institutes of Health and the National Cancer Institute. [Extracted from the article]

A recent study from Banasthali Vidyapith explores the role of circular RNAs (circRNAs) in colorectal, gastric, liver, and lung cancers. The research highlights the potential of circRNAs as cancer biomarkers and drug targets, with 577 circRNAs identified across these cancer types. The study delves into how circRNAs modulate gene expression in cancer and discusses the challenges and prospects of using circRNAs for cancer diagnostics and therapies. This comprehensive analysis aims to advance cancer research and develop innovative therapies and diagnostics. [Extracted from the article]

A recent study from Sichuan University explored the relationship between microbiota dysbiosis and early-stage lung cancer. The research found differences in microbial composition and metabolic status between early-stage lung adenocarcinoma and squamous carcinoma. Specific flora such as Ralstonia, Feacalibacterium, and Blautia were identified as playing roles in tumor development and progression. This study sheds light on the carcinogenesis of early-stage lung cancer and provides new insights into potential mechanisms. [Extracted from the article]

Researchers at Zhejiang University School of Medicine conducted a study on clear cell renal cell carcinoma (ccRCC) to investigate the cellular and regional heterogeneity of the disease. They identified a novel cancer-promoting subset of regulatory T (Treg) cells that have stronger immunosuppressive function and are associated with a worse prognosis in ccRCC patients. The study also revealed interactions between these Treg cells and tumor-associated macrophages, providing new insights into potential therapeutic targets for ccRCC. The research was published in the Journal for ImmunoTherapy of Cancer and can be accessed for free online. [Extracted from the article]

Researchers at Damietta University have developed a new thiazole derivative with potential anticancer properties and as a topoisomerase II inhibitor. The compound showed strong cytotoxic effects on human cancer cell lines, particularly HepG-2 and MCF-7, while binding strongly to CT-DNA through intercalative mode. Molecular docking studies supported the compound's DNA binding affinity, suggesting a promising avenue for cancer therapy innovation. The study was published in Scientific Reports and can be accessed for further information. [Extracted from the article]

A recent study conducted at the Pravara Institute of Medical Sciences focused on the impact of the Active Cycle of Breathing Technique (ACBT) and Incentive Spirometry on a patient with pleural effusion caused by malignant lung carcinoma. The study found that these interventions significantly improved chest expansion, dyspnoea, and SPO2 levels in the patient. The research highlights the potential benefits of ACBT and Incentive Spirometry in enhancing the quality of life for lung carcinoma patients. [Extracted from the article]

A recent study conducted by researchers at Guangxi Medical University in China explored the impact of Clonorchis sinensis (C. sinensis) infection on hepatocellular carcinoma (HCC) patients. The study found that C. sinensis infection was associated with younger age at cancer onset, male predominance, advanced cancer stage, liver cirrhosis, and microvascular invasion in HCC patients. Additionally, the infection correlated with shorter overall survival and recurrence-free survival, as well as altered levels of blood lipids. The research suggests that C. sinensis triggers inflammation, insulin resistance, and pro-tumor immune escape, providing insights into potential therapeutic targets for HCC patients co-infected with C. sinensis. [Extracted from the article]

A recent report from Inonu University in Malatya, Turkey, discusses the use of procalcitonin (PCT) and Ki-67 expression levels in predicting the biological behavior of hepatocellular carcinoma (HCC) after liver transplantation. The study analyzed 86 HCC patients who underwent liver transplantation and found that Ki-67 levels exceeding 5% significantly affected disease-free survival and overall survival. The research suggests that Ki-67 can be used as a predictive biomarker for HCC, and further studies on standardized PCT antibody staining are needed to determine its potential as a biomarker. [Extracted from the article]

A recent study conducted by Centro Nacional de Investigaciones Oncologicas (CNIO) in Madrid, Spain, explores the potential benefits of cold exposure in treating liver cancer. The research suggests that chronic cold exposure can prolong lifespan in mice with hepatocellular carcinoma (HCC), enhance liver health, and suppress the development of aggressive HCC by reinstating NAD+ levels. These findings highlight the role of cold therapy in attenuating HCC development and potentially other malignancies involving NAD+ modulation. For more information, readers can access the full article in Cell Stress. [Extracted from the article]

A recent study conducted by researchers at Chonnam National University in Gwangju, South Korea, focused on the use of radiofrequency ablation (RFA) as a treatment for hepatocellular carcinoma (HCC). The study analyzed data from 636 patients with HCC who underwent RFA treatment between 2008 and 2017, revealing that the albumin-bilirubin (ALBI) grade was a significant predictor of tumor recurrence and prognosis. The researchers concluded that the ALBI grade could help clinicians identify high-risk patients and improve treatment strategies for individuals with HCC. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Soochow University in China explored the impact of a nursing model based on the Transtheoretical model on male patients with primary liver cancer. The study found that patients who received the intervention showed improved self-management abilities, reduced negative emotions, and better quality of life compared to those who received standard treatment. The research suggests that the behavioral stage change theory collaborative nursing model could be beneficial for male patients undergoing primary hepatocellular carcinoma resection. [Extracted from the article]

A recent study conducted by researchers at the University of Tsukuba in Japan focused on enhancing the therapeutic efficacy of sorafenib, a drug used in the treatment of non-small-cell lung cancer. The study developed silica-containing antioxidant nanoparticles to improve drug stability and reduce adverse effects associated with sorafenib. Results showed that the nanoparticles effectively suppressed tumor growth and improved survival rates in a mouse model of Lewis lung carcinoma, highlighting their potential to enhance treatment outcomes while minimizing side effects. This research offers promise for improving therapeutic outcomes in lung cancer treatment. [Extracted from the article]

Researchers from Aarhus University Hospital in Denmark have conducted a study on squamous cell carcinoma, focusing on the clinical utility of circulating human papillomavirus (HPV) across different types of SCCs. The study found that HPV can be detected in circulating tumor DNA, making it a potential biomarker for HPV-associated cancers. The researchers reviewed 41 studies on cervical, head and neck, and anal SCCs, emphasizing the need for coordinated studies to validate the clinical potential of circulating HPV as a biomarker. The full article can be accessed in Acta Oncologica, with contact information for the researchers provided for further inquiries. [Extracted from the article]

A recent study published in the journal Diagnostics investigated the expression of CD47 in benign and malignant renal cell tumors and its correlation with prognostic parameters. The research, conducted in Gaziantep, Turkey, found a significant relationship between CD47 expression and survival, metastasis, and capsule invasion in unclassified renal cell carcinoma cases. The study suggests the need for further large-scale research to determine the expression profile of CD47 in renal cell tumors. For more information, readers can access the full article at https://doi.org/10.3390/diagnostics15010053. [Extracted from the article]

The article discusses the use of proteomic profiling to identify predictive signatures of response to treatments for advanced hepatocellular carcinoma (HCC). It highlights the importance of immunotherapies, specifically the combination of atezolizumab/bevacizumab, as a revolutionary first-line systemic treatment for HCC. The study found specific proteomic signatures that can predict treatment response and shed light on biological pathways involved in treatment resistance, offering insights to optimize patient management. [Extracted from the article]

A study conducted at Southern Medical University in Guangzhou, China, evaluated the effectiveness of postoperative immunotherapy for esophageal squamous cell carcinoma (ESCC) after radical surgery. The research compared postoperative adjuvant immunotherapy combined with chemotherapy to postoperative adjuvant chemotherapy alone in patients with locally advanced ESCC. The study found that postoperative immunotherapy did not result in better disease-free recurrence rates compared to postoperative adjuvant therapy, but suggested that the role of immunotherapy in ESCC treatment may expand in the future. [Extracted from the article]

A recent study conducted by investigators from the Dana-Farber Cancer Institute in Boston, Massachusetts, focused on real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma. The study found that approximately half of patients were eligible for maintenance avelumab after receiving first-line platinum-based chemotherapy, but only one-fifth actually received it. Overall survival rates were short for the population treated with first-line chemotherapy, despite the availability of maintenance avelumab. The study highlights the importance of treatment options that benefit all patients with urothelial carcinoma, regardless of eligibility for specific therapies. [Extracted from the article]